Parataxis Holdings Announces Bitcoin Treasury Move with Bridge Biotherapeutics
Deal News | Jun 20, 2025 | PR Newswire Cision Parataxis Holdings LLC
Parataxis Holdings LLC, an extension of Parataxis Capital Management LLC, has announced the signing of a definitive agreement to invest 25 billion KRW in Bridge Biotherapeutics Inc, a South Korean biotech company listed on KOSDAQ. This strategic financial move is set to create a new entity named Parataxis Korea, positioning it as a pioneering Bitcoin-native treasury company in South Korea. The deal paves the way for Parataxis Holdings to have a controlling stake in Bridge Biotherapeutics. Upon completion, the corporate identity will shift to align with the new strategy, and the focus will be on building a substantial BTC treasury and enhancing institutional access to Bitcoin. Edward Chin and Andrew Kim from Parataxis will join the Board and executive leadership to guide the new company's direction, emphasizing disciplined capital management. Shin & Kim LLC and Deloitte are providing legal and financial advisory services, respectively. This transaction highlights a growing institutional interest in Bitcoin treasury strategies and underlines South Korea's importance as a burgeoning market for BTC adoption.
Sectors
- Biotechnology
- Financial Services - Digital Asset Management
- Investment Management
Geography
- South Korea – The transaction involves Bridge Biotherapeutics, Inc., a South Korean biotech company, and the establishment of a BTC treasury company in South Korea.
- United States – Parataxis Holdings LLC, headquartered in New York, plays a central role in orchestrating this investment and strategic move into South Korea.
Industry
- Biotechnology – Bridge Biotherapeutics operates within the biotechnology sector, focusing on developing therapeutics for ulcerative colitis, fibrotic diseases, and cancer.
- Financial Services - Digital Asset Management – Parataxis Holdings LLC is creating a BTC-native treasury platform through its investment, combining financial management and digital asset strategies.
- Investment Management – Parataxis Capital provides investment management services focusing on digital assets, influencing the strategic direction of the deal.
Financials
- 25 billion KRW – The investment amount by Parataxis Holdings in Bridge Biotherapeutics for controlling interest.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Parataxis Holdings LLC | Bidding Company | Companies | An affiliate of Parataxis Capital aiming to create a Bitcoin treasury company in South Korea through the acquisition of Bridge Biotherapeutics. |
| Bridge Biotherapeutics, Inc. | Target Company | Companies | A South Korean biotech company engaged in developing therapeutics, being acquired for Bitcoin treasury strategy. |
| Parataxis Capital Management LLC | Investment Manager | Companies | An investment firm focused on digital assets, facilitating the strategic direction of the BTC treasury initiative. |
| Edward Chin | CEO/Board Member | People | Founder of Parataxis Holdings, joining the Board of Directors for the new company structure. |
| Andrew Kim | CEO of Parataxis Korea | People | Partner at Parataxis Capital who will assume the role of CEO for the new entity post-acquisition. |
| James Jungkue Lee | Co-founder of Bridge Bio | People | Will remain involved on the Board and lead the core biotech efforts. |
| Shin & Kim LLC | Legal Advisor | Companies | Legal advisors for Parataxis Korea Fund I LLC in the transaction. |
| Deloitte | Financial Advisor | Companies | Financial advisors for Parataxis Korea Fund I LLC, aiding in the transaction process. |